We use cookies to help provide you with the best possible online experience. Learn more

Financial Reports

RaySearch Laboratories AB (publ) Interim Report January 1 – June 30, 2009

JANUARY 1 – JUNE 30, 2009

• Net sales for the period amounted to SEK 34.7 M (27.6) • Profit after tax was SEK 12.3 M (4.2) and earnings per share amounted to SEK 0.36 (0.12) • Operating profit was SEK 16.6 M (4.4) • Cash flow totaled SEK 1.8 M (neg: 15.1) • The collaboration with Nucletron was extended in January with two new products for treatment planning • The first product from the collaboration with TomoTherapy received FDA clearance in January and has been launched • The new VMAT product from the collaboration with Philips was launched in April • A collaboration agreement with Siemens was signed in May • Three products included in the collaboration with Varian were launched in June • Breakthrough order for proton treatment planning system secured in June “Our first commercial order for a proton treatment planning system was a real breakthrough. This agreement means that we have sold a system directly to a clinic for the first time, which is an important milestone in RaySearch’s history,” says Johan Löf, CEO of RaySearch. ”In addition, several of our new products were launched by our commercial partners during the second quarter. Therefore we see favorable conditions for a positive development for the remainder of the year,” concludes Johan Löf.